US equities |
TSLA $395.17 ▲+6.17% MU $891.29 ▲+1.57% SPCX $146.87 ▼-0.42% NVDA $215.10 ▲+1.96% META $637.44 ▼-0.81% SNDK $1,250.66 ▲+1.02% AAPL $344.57 ▼-0.91% AMZN $250.50 ▲+1.01%
FinancialContent

Edwards Lifesciences (NY:EW)

90.17 +1.10 (+1.23%)
Delayed Quote Updated: 10:22 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Edwards Lifesciences

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stay informed with the top movers within the S&P500 index on Thursday. ↗
Via Chartmill
News headline image
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead ↗
Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its... 
Via MarketBeat
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Edwards Lifesciences (NYSE:EW) Raises Guidance After Solid Q2 Earnings, Stock Surges 6% ↗
Via Chartmill
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Edwards Lifesciences Corp (NYSE:EW) Shares Surge After Q1 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
Top S&P500 movers in Friday's session ↗
Via Chartmill
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
News headline image
Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years ↗
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an annualized basis producing an average annual return of 17.22%. Currently, Edwards Lifesciences has a... 
Via Benzinga
News headline image
$100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today ↗
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a... 
Via Benzinga
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Edwards Lifesciences Q2 Earnings Call Highlights ↗
Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral... 
Via MarketBeat
Topics Earnings
Which S&P500 stocks are moving after the closing bell on Thursday? ↗
Via Chartmill
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
Top gainers and losers in the S&P500 index during Thursday's after-hours session. ↗
Via Chartmill
News headline image
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Topics Lawsuit
News headline image
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)
As of April 1, 2026, Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a... 
Via Finterra
Topics Economy Lawsuit Product Recall
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing. 
Via The Motley Fool
News headline image
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗
RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials. 
Via The Motley Fool
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire... 
Via MarketMinute
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
The Return of the Mega-Deal: How 2026’s Regulatory Pragmatism is Reshaping Corporate America
The U.S. mergers and acquisitions (M&A) landscape has entered a definitive new era in early 2026, marked by what analysts are calling a "Strategic Rebound." After years of aggressive antitrust... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗
Via MarketBeat
Unusual volume S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Edwards Lifesciences (EW) Earnings Transcript ↗
Edwards Lifesciences (EW) Earnings Transcript 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >